Metastatik Meme Kanserinde Radyoterapi

MalmgrenJ, Hurlbert M, Atwood M, et al: Examination of a paradox: Recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011. Breast Cancer Res Treat 174:505-514, 2019 File DM, Pascual T, Deal AM, et al: Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. 196:153-162, 2022 Pusztai L, Rozenblit M, Dubsky P, et al. De Novo Oligometastatic Breast Cancer Journal of Clinical Oncology Volume 41,number 34 August 22, 2023

Greenberg PA, Hortobagyi GN, Smith TL,et al Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–2205. doi: 10.1200/JCO.1996.14.8.2197.

Potters L, Kavanagh B, Galvin JM,et al. American Society for Therapeutic Radiology and Oncology; American College of Radiology. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76:326–332. doi: 10.1016/j.ijrobp.2009.09.042 Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118:2962–2970. doi: 10.1002/cncr.26611 Esen Ç, Gültekin M, Yıldız F. et al.World Role of radiotherapy in oligometastatic breast cancer: Review of the literatüre J Clin Oncol,22 Jan 24;13(1):39–48.

Hellman, S, Weichselbaum, R. R. Oligometastases.J Clinic Oncology.1995;13:8-10 https://doi.org/10.1200/jco.1995.13.1.8

Lievens Y, Guckenberger M, Gomez D, et al: Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol l 148:157-166, 2020 Guckenberger, M. ∙ Lievens, Y. ∙ Bouma, A.B et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation Lancet Oncol. 2020; 21:e18-e28 Daily K, Douglas E, Romitti PA, et al: Epidemiology of de novo metastatic breast cancer. Clin Breast Cancer 21:302-308, 2021

Lacaze JL, Aziza R, Chira C, et al: Diagnosis, biology and epidemiology of oligometastatic breast cancer. Breast 59:144-156, 2021

Liu W, Bahig H, Palma DA: Oligometastases: Emerging evidence. J Clin Oncol 40:4250-4260, 2022 Lehrer EJ, Singh R, Wang M, et al: Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: A systematic review and meta-analysis. JAMA Onc 7:92-106, 2021 Stahl K, Wong W, Dodge D, et al: Benefits of surgical treatment of stage IV breast cancer for patients with known hormone receptor and HER2 status. Ann Surg Oncol 28:2646-2658 Palma DA, Olson R, Harrow S, et al: Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial. JClinc Oncolgy 38:2830-2838, 2020

Piroth, M.D, Krug D, Feyer, P et al. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective Strahlenther Onkol. 2022; 198:601-61 Harrow S, Palma, D.A, Olson R, et al.Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term OutcomesInt J Radiat Oncol Biol Phys. 2022; 114:611-616

David S.P, Siva S, Bressel M et al.Stereotactic Ablative Body Radiotherapy (SABR) for Oligoprogressive ER-Positive Breast Cancer (AVATAR): A Phase II Prospective Multicenter Trial Presented at: 2023 American society for radiation Oncology annual meeting 2023 September 30-October 4, 2023 Abstract LBA 09

Chmura SJ, Winter KA, Woodward WA, et al: NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol 40, 2022

Kwapisz, D. Oligometastatic breast cancer. Breast Cancer 2019, 26, 138–146.

De Vin T Engels, B.; Gevaert, T.; Storme, G.; De Ridder, M. Stereotactic radiotherapy for oligometastatic cancer: A prognostic model for survival. Ann. Oncol. 2014, 25, 467–471.

Tree, A.C, Khoo, V.S, Eeles R.A et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013, 14, e28–e37

Milano M.T, Katz, A.W, Zhang, H; et al. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. Radiother. Oncol. 2019, 131, 45–51.

Kobayashi T, Ichiba T, Sakuyama T, at al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19:218–237. doi: 10.1007/s12282-012-0347-0. Wong, A.C, Watson, S.P, Pitroda, S.P, et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT): Survival after SBRT for Oligometastases. Cancer 2016, 122, 2242–2250

Trovo, M, Furlan C, Polesel J, et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother. Oncol. 2018, 126, 177–180 Yoo G.S, Yu, J.I, Park, W, et al. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiat. Oncol. J. 2015, 33, 301. Yilmaz MT, Gültekin M, Sarı Yüce Stereotactic Ablative Radiotherapy for Bone-Only Oligometastatic Breast Cancer: On a Quest to Find the Optimum Cohort , Clinical Oncology Volume 37,103670 January 2025 Badwe R, Hawaldar R, Nair N, et al: Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomized controlled trial. Lancet Oncol 16:1380-1388, 2015 Fitzal F, Bjelic-Radisic V, Knauer M, et al: Impact of breast surgery in primary metastasized breast cancer: Outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE Trial. Ann Surg 269:1163-1169, 2019

Khan SA, Zhao F, Goldstein LJ, et al: Early local therapy for the primary site in de novo stage IV breast cancer: Results of a randomized clinical trial (EA2108). J Clin Oncol 40:978-987, 2022 Gennari A, André F, Barrios CH, et al: ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆. Ann Onc 32:1475-1495, 2021 34-Gultekin M, Yazici O, Eren G,et al. Impact of locoregional treatment on survival in patients presented with metastatic breast carcinoma. Breast. 2014;23:775–783. doi:

Le Scodan R, Stevens D, Brain E, at al. A. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol. 2009;27:1375–1381. doi: 0.1200/JCO.2008.19.5396. Neuman HB, Morrogh M, Gonen M, et al. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer. 2010;116:1226–1233. doi: 10.1002/cncr.24873 Viani, G.A. Gouveia, A.G, Louie, A.V.et al.Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis Radiother Oncol. 2021; 164:245-250 Armstrong S, Makris A, Belessiotis-Richards K, et al. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.Clinical Oncology Volume 36 , Issue 6,P362-369June 2024

Goblirsch, M, Mathews W, Lynch, Cet al. Radiation Treatment Decreases Bone Cancer Pain, Osteolysis and Tumor Size. Radiat. Res. 2004, 161, 228–234.

Vakaet, L.A.L.; Boterberg, T. Pain control by ionizing radiation of bone metastasis. Int. J. Dev. Biol. 2004, 48, 599–606.

Alongi, F, Arcangeli, S, Filippi, A.R.et al. Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. Oncologist 2012, 17, 1100–1107.

Costa, S. Reagan, M.R. Therapeutic Irradiation: Consequences for Bone and Bone Marrow Adipose Tissue. Front. Endocrinol. 2019, 10, 587.

D’Oronzo, S, Coleman, R, Brown, J, et al . Metastatic bone disease: Pathogenesis and therapeutic options. J. Bone Oncol. 2019, 15, 100205

Marazzi F,OrlandiA, Manfrida S,et al. Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians . Cancers 2020, 12(9), 2390; https://doi.org/10.3390/cancers1209239

Chow E, Wu, J, Hoskin P,et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother. Oncol. 2002, 64, 275–280. 46-Chow E, Hoskin P, Mitera G,et al. Update of the International Consensus on Palliative Radiotherapy Endpoints for Future Clinical Trials in Bone Metastases. Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 1730–1737. Gerszten, P.C, Burton S.A, Welch W.C,et al.Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer 2005, 104, 2244–2254

Kam T.Y, Chan O.S,H, Hung A.W.M, et al. Utilization of stereotactic ablative radiotherapy in oligometastatic & oligoprogressive skeletal metastases: Results and pattern of failure. Asia-Pac. J. Clin. Oncol. 2019, 15, 14–19. 49- Farooqi A, Bishop A.J, Narang S, et al. Outcomes after Hypofractionated Dose-Escalation using a Simultaneous Integrated Boost Technique for Treatment of Spine Metastases Not Amenable to Stereotactic Radiosurgery. Pract. Radiat. Oncol. 2019

Maranzano E, Trippa F, Casale M,et al. V. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol. 2009;93:174–9. doi: 10.1016/j.radonc.2009.05.012

Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52:2349–2354. doi: 10.1002/1097

Evans AJ, James JJ, Cornford EJ,et al . Brain metastases from breast cancer: Identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004;16:345–349. doi: 10.1016/j.clon.2004.03.012 Gabos Z, Sinha R, Hanson J,at all. B. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24:5658–5663. doi: 10.1200/JCO.2006.07.0250. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Path 2006; 30: 1097-1104.

Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003; 97: 2972

Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990.

Vecht CJ, Haaxma‐Reiche H, Noordijk EM, et al: Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery. Ann Neurol 33:583-590, 1993

Wu A, Lindner G, Maitz A, et al: Physics of gamma knife approach on convergent beams in stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 18:941-949, 1990

Sankey EW, Tsvankin V, Grabowski MM, et al: Operative and peri‐operative considerations in the management of brain metastasis. Cancer Med 8:6809-6831, 2019 60-Vogelbaum MA, Brown PD, Messersmith H, et al: Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40:492-516, 2022

Hunter GK, Suh JH, Reuther AM, et al: Treatment of five or more brain metastases with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 83:1394-1398, 2012

Kondziolka D, Kalkanis SN, Mehta MP, et al: It is time to reevaluate the management of patients with brain metastases. Neurosurgery 75:1-9, 2014

Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295: 2483-2491.

Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1 to 3 cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011; 29: 134-141.

Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with 1 to 3 brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363: 1665-1672.

Kelly P, Lin N, Claus E et al. Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors Cancer. 2012 Apr 15;118(8):2014-20. doi: 10.1002/cncr.26343. Epub 2011 Sep 14. Kühnöl J, Kühnöl C, Vordermak D. Radiotherapy of brain metastases from breast cancer: Treatment results and prognostic factors. Oncol Lett. 2016 Mar 17;11(5):3223–3227. doi: 10.3892/ol.2016.4349 Mix M, ElmarzoukyR, O'Connor T, et al. Clinical outcomes in patients with brain metastases from breast cancer treated with single-session radiosurgery or whole brain radiotherapy J Neurosurg 2016 Dec;125(Suppl 1):26-30. doi: 10.3171/2016.7.GKS161541 69- Paul J, Kelly MB, Nancy U. et al. Salvage stereotactic radiosurgery for breast cancer brain metastases Outcomes and prognostic factors https://doi.org/10.1002/cncr.26343

Almeida ND, Kuo C, Schrand TV, et al. Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis Cancers (Basel). 2024 Oct 21;16(20):3551. doi: 10.3390/cancers16203551 Scorsetti M, Franceschini D, De Rose F,et al. The role of SBRT in oligometastatic patients with liver metastases from breast cancer Rep Pract Oncol Radiother . 2017 Mar-Apr;22(2):163-169. doi: 10.1016/j.rpor.2016.07.008. Epub 2016 Sep 5.

Dellas K. Does radiotherapy have curative potential in metastatic patients? The concept of local therapy in oligometastatic breast cancer. Breast Care. 2011;6:363–368. doi: 10.1159/000333115. Milano M.T, Katz A.W, Zhang H.et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83:878–886. doi: 10.1016/j.ijrobp.2011.08.036 Rusthoven K.E., Kavanagh B.D., Cardenes H. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–1578. doi: 10.1200/JCO.2008.19.6329. Chang D.T, Swaminath A, Kozak M. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117(17):4060–4069. doi: 10.1002/cncr.25997. Lee M.T, Kim J.J. Dinniwell R. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585–1591. doi: 10.1200/JCO.2008.20.0600. Stanowicka-Grada M and Senkus E. Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Curr Treat Options Oncol. (2023) 24:1633–50. doi: 10.1007/s11864-023-01137-5 Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. (2020) 21:519–30. doi: 10.1016/S1470-2045(19)30863-0 von Minckwitz G, Procter M, de Azambuja E, Zardavas D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. (2017) 377:122–31. doi: 10.1056/NEJMoa1703643 RenT, Wang X, Luo S, et al. Radiotherapy improves survival in HER2-positive breast cancer with lung metastases: a retrospective study with artificial intelligence-based prognostic modeling Frontiers in Oncology 16 July 2025 Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1633448 Dvir K, Giordano S, and Leone JP. Immunotherapy in breast cancer. Int J Mol Sci. (2024) 25:7517. doi: 10.3390/ijms25147517

Cortés J, Hurvitz SA, Im SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. (2024) 30:2208–15. doi: 10.1038/s41591-024-03021-

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. (2020) 382:610–21. doi: 10.1056/NEJMoa1914510